Longevity · Compounded & Approved Peptides

Peptide Therapy: Uses, Types, and What's Actually FDA-Approved

Updated

What they are

What Peptides Are

Peptides are short chains of amino acids — usually fewer than 50 — that act as signaling molecules. The body produces thousands naturally (insulin, oxytocin, glucagon, GHRH). Therapeutic peptides mimic or modulate these endogenous signals.

Calling something a “peptide” says nothing about whether it works, whether it is safe, or whether it is legal. The category spans blockbuster FDA-approved drugs and unregulated research chemicals sold by mail.

FDA-approved

The Peptides That Are Actually FDA-Approved

A short list of peptides has full FDA approval with the manufacturing and safety data approval requires:

  • ·Semaglutide (Ozempic, Wegovy, Rybelsus) — diabetes and obesity.
  • ·Tirzepatide (Mounjaro, Zepbound) — diabetes and obesity.
  • ·Tesamorelin (Egrifta) — HIV-associated lipodystrophy; a GHRH analog.
  • ·Liraglutide (Saxenda, Victoza) — obesity and diabetes.
  • ·PT-141/bremelanotide (Vyleesi) — premenopausal HSDD.
  • ·Various insulin analogs.

Compounded / gray-market

Compounded and Research-Chemical Peptides

The peptides most heavily marketed for performance and longevity are not FDA-approved:

  • ·BPC-157 — claimed for tendon, joint, and GI healing. Human evidence is essentially absent; nearly all data is rodent.
  • ·TB-500 (thymosin beta-4 fragment) — claimed for muscle and tissue repair. Limited human data.
  • ·GHK-Cu — copper peptide, mostly topical evidence in dermatology.
  • ·CJC-1295, ipamorelin, sermorelin — GH secretagogues. Sermorelin's branded product was discontinued; current use is compounded.
  • ·Selank, semax — Russian-origin nootropics with no U.S. approval.
  • ·Melanotan II — tanning peptide; serious adverse events documented.

In late 2023 the FDA placed many of these on its 503A Category 2 list. Their status changed in 2026 — see below.

2026 update

What changed in 2026 (FDA status caution)

  • ·April 22, 2026: FDA removed 12 peptides, including BPC-157 and TB-500, from its 503A Category 2 safety-concern list after the nominations were withdrawn (Orrick summary). Removal is not approval and does not place them on the 503A bulks list.
  • ·Category 2 today: per FDA list updated May 14, 2026, it holds six substances, including ibutamoren and kisspeptin-10. Non-injectable GHK-Cu is back under evaluation in Category 1.
  • ·Oct. 30, 2026: HHS announced an interim enforcement-discretion policy for compounding six peptides (BPC-157, TB-500, Epitalon, Semax, KPV, MOTS-c) under strict conditions. It is not FDA approval; compounded drugs remain unapproved; the policy is non-binding and can be revisited; state pharmacy rules still apply. Final status depends on FDA rulemaking on the 503A bulks list.
  • ·Public comments on Docket HHS-OASH-2026-0496 close Nov. 13, 2026, 11:59 p.m. Eastern.

None of these steps adds new evidence that the peptides work; ask your physician what the evidence shows for your specific indication. For a broader overview, see What Is Peptide Therapy?.

Evidence

Honest Evidence Levels

  • ·Strong human evidence: GLP-1 and dual-incretin peptides; tesamorelin for the labeled indication.
  • ·Moderate human evidence: GH secretagogues for confirmed adult GH deficiency.
  • ·Limited human evidence: BPC-157, TB-500 — promising mechanism, mostly rodent data.
  • ·Topical or local evidence only: GHK-Cu in dermatology.
  • ·Anti-aging / longevity outcome data: essentially none for the marketed compounded peptides.

Risks

Real Risks — Source, Sterility, Dosing

The risk of compounded peptide therapy is rarely the molecule itself. It is the supply chain.

  • ·Source. Many clinics obtain product from suppliers not intended for human use; identity and purity vary.
  • ·Sterility. Self-injection of contaminated peptide has produced documented infections and sepsis.
  • ·Dosing. Without FDA-approved labeling, dosing is extrapolated from animal studies; safe-dose data is thin.
  • ·Long-term effects on cancer biology, insulin signaling, and cardiovascular risk are not fully characterized.

The physician version

What Legitimate Peptide Prescribing Looks Like

A physician program that uses peptides responsibly looks different from a clinic that sells them:

  • ·A specific documented clinical indication the chosen peptide actually addresses.
  • ·FDA-approved product where one exists for the indication.
  • ·Compounding only from 503A/503B pharmacies operating within current FDA guidance.
  • ·Baseline labs, hormone panel where relevant, structured follow-up.
  • ·Honest conversation about what the evidence does and does not support.

Featured doctors

Featured Haute MD Physicians

Featured doctors: Haute MD members in internal and concierge medicine include Dr. Ari Cohen in Aventura, Florida, and Dr. Kern Brar in the San Diego area. Browse Find a Doctor. Haute MD members are physicians who joined our editorial network. Editorial selection, not a ranking.

Frequently asked

Common questions

What are peptides actually used for?

Approved peptide medications treat diabetes, obesity, HIV-associated lipodystrophy, sexual desire disorder, and specific other conditions. Wellness peptides target muscle, recovery, and longevity claims with much weaker evidence.

Are peptides FDA-approved?

Some are — semaglutide, tirzepatide, tesamorelin, liraglutide, bremelanotide. Most peptides sold by longevity clinics are compounded or research chemicals, not FDA-approved drugs.

Is BPC-157 safe and effective?

Human evidence is essentially absent. Animal data is interesting; that is not the same as proven in people. FDA removed BPC-157 from its Category 2 list in April 2026 after the nomination was withdrawn, and HHS's October 2026 interim policy covers its compounding under strict conditions — neither is an FDA approval or proof it works.

Are compounded peptides legal in 2026?

It depends on the peptide, the pharmacy and the state. Compounded drugs are not FDA-approved. In 2026, HHS said it will not take enforcement action against 503A compounding of six specific peptides when all of its conditions are met, while FDA decides through rulemaking whether to add them to the 503A bulks list. Other peptides, and research-use-only products, are not covered.

What is the 503A Category 2 list?

FDA describes Category 2 as bulk drug substances that raise significant safety risks. As of the May 14, 2026 list, it includes six substances (including ibutamoren and kisspeptin-10); BPC-157 is no longer on it.

How do I find a legitimate peptide physician?

Look for board-certified physicians who prescribe FDA-approved peptides where they exist, work with reputable compounding pharmacies, document a clinical indication, and run baseline and follow-up labs.

References

Sources

  1. 1.Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026) — U.S. Food and Drug Administration, 2026.
  2. 2.Tesamorelin (Egrifta) Prescribing Information — U.S. Food and Drug Administration, 2014.
  3. 3.BPC-157 — Review of Preclinical Evidence — Current Pharmaceutical Design, 2018.
  4. 4.Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (FR Doc. 2026-22192, Oct. 30, 2026) — Federal Register, 2026.
  5. 5.HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides (Nov. 4, 2026) — Holland & Knight, 2026.
  6. 6.FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings (Apr. 16, 2026) — Orrick, 2026.

Related

Continue reading

Haute MD Network

Consult a Haute MD Concierge & Longevity Medicine physician

Choose a market to browse editorially featured physicians.

Browse all physicians